Eris Lifesciences Ltd Stock Price Today (NSE: ERIS)
Fundamental Score
Eris Lifesciences Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Eris Lifesciences Ltd share price today is ₹1328.40, up +0.00% on NSE/BSE as of 19 February 2026. Eris Lifesciences Ltd (ERIS) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹21.54K (Cr). The 52-week high for ERIS share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 51.82x, ERIS is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 12.88% and a debt-to-equity ratio of 0.77.
Eris Lifesciences Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Eris Lifesciences Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Eris Lifesciences Share Price Analysis: A ROCE-Focused Perspective
The pharmaceutical industry, characterized by high research and development costs and stringent regulatory hurdles, often sees significant price volatility contingent on drug approvals and patent expirations. This analysis examines the current valuation of the Eris Lifesciences share price (₹1431.0) through the lens of Return on Capital Employed (ROCE) efficiency, a key metric for evaluating profitability relative to capital investments. With a PE ratio of 51.82 and a ROCE of 12.22%, Eris Lifesciences presents an interesting case for investigation.
A ROCE of 12.22% indicates the company's ability to generate profits from its invested capital. This metric is crucial for assessing the sustainability of Eris Lifesciences' economic moat. While a positive ROCE is encouraging, benchmarking against its peers is essential. Consider
Mankind Pharma Ltd, a significant player in the industry. Further investigation would be needed to understand if Mankind Pharma Ltd exhibits superior operational efficiency, potentially driven by stronger management and optimized resource allocation. Management quality, while difficult to quantify directly, can have an outsized impact on a company's ROCE trajectory through strategic investment decisions and operational improvements. A deeper comparative analysis of strategic management decisions between Eris Lifesciences and its peers would prove valuable.The relatively high PE ratio of 51.82 suggests that the market has high expectations for future earnings growth. However, the 12.22% ROCE warrants caution, especially when compared to industry benchmarks. While Eris Lifesciences appears to be generating profit from its assets, a consistently higher ROCE strengthens the company's competitive advantage by providing more capital to reinvest in future growth opportunities, such as new product development or market expansion.
This financial analysis is part of a more comprehensive 80-parameter fundamental audit, verified by Sweta Mishra, focusing on various quantitative and qualitative aspects of Eris Lifesciences. This analysis aims to present an objective view based on available data and industry context.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Eris Lifesciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ERIS across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Operating Margins (34.48%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (31.23%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (21.92% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Cash Generation (₹1325.32 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (54.85%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 26.57%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
3 factors identified
Premium Valuation Risk (P/E: 51.82x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (3.65% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (3.71% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Eris Lifesciences Ltd Financial Statements
Comprehensive financial data for Eris Lifesciences Ltd including income statement, balance sheet and cash flow
About ERIS (Eris Lifesciences Ltd)
Eris Lifesciences Ltd (ERIS) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹21.54K (Cr). Eris Lifesciences Ltd has delivered a Return on Equity (ROE) of 12.88% and a ROCE of 12.22%. The debt-to-equity ratio stands at 0.77, reflecting the company's capital structure. Investors tracking ERIS share price can monitor key metrics including P/E ratio, promoter holding of 54.85%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
ERIS Share Price: Frequently Asked Questions
What is the current share price of Eris Lifesciences Ltd (ERIS)?
As of 19 Feb 2026, 10:08 am IST, Eris Lifesciences Ltd share price is ₹1328.40. The ERIS stock has a market capitalisation of ₹21.54K (Cr) on NSE/BSE.
Is ERIS share price Overvalued or Undervalued?
ERIS share price is currently trading at a P/E ratio of 51.82x, compared to the industry average of 31.77x. Based on this relative valuation, the Eris Lifesciences Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of ERIS share price?
The 52-week high of ERIS share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Eris Lifesciences Ltd share price?
Key factors influencing ERIS share price include quarterly earnings growth (Sales Growth: 6.91%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Eris Lifesciences Ltd a good stock for long-term investment?
Eris Lifesciences Ltd shows a 5-year Profit Growth of 3.71% and an ROE of 12.88%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.77 before investing in ERIS shares.
How does Eris Lifesciences Ltd compare with its industry peers?
Eris Lifesciences Ltd competes with major peers in the Pharmaceuticals. Investors should compare ERIS share price P/E of 51.82x and ROE of 12.88% against the industry averages to determine competitive standing.
What is the P/E ratio of ERIS and what does it mean?
ERIS share price has a P/E ratio of 51.82x compared to the industry average of 31.77x. Investors pay ₹52 for every ₹1 of annual earnings.
How is ERIS performing according to Bull Run's analysis?
ERIS has a Bull Run fundamental score of 36.4/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ERIS belong to?
ERIS operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Eris Lifesciences Ltd share price.
What is Return on Equity (ROE) and why is it important for ERIS?
ERIS has an ROE of 12.88%, which shows decent profitability but room for improvement. ROE measures how efficiently Eris Lifesciences Ltd generates profits from shareholders capital.
How is ERIS debt-to-equity ratio and what does it indicate?
ERIS has a debt-to-equity ratio of 0.77, which indicates moderate leverage that should be monitored.
What is ERIS dividend yield and is it a good dividend stock?
ERIS offers a dividend yield of 0.46%, meaning you receive ₹0.46 annual dividend for every ₹100 invested in Eris Lifesciences Ltd shares.
How has ERIS share price grown over the past 5 years?
ERIS has achieved 5-year growth rates of: Sales Growth 21.92%, Profit Growth 3.71%, and EPS Growth 3.65%.
What is the promoter holding in ERIS and why does it matter?
Promoters hold 54.85% of ERIS shares, with 16.92% pledged. High promoter holding often indicates strong management confidence in Eris Lifesciences Ltd.
What is ERIS market capitalisation category?
ERIS has a market capitalisation of ₹21544 crores, placing it in the Large-cap category.
How volatile is ERIS stock?
ERIS has a beta of N/A. A beta > 1 suggests the Eris Lifesciences Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ERIS operating profit margin trend?
ERIS has a 5-year average Operating Profit Margin (OPM) of 34.48%, indicating the company's operational efficiency.
How is ERIS quarterly performance?
Recent quarterly performance shows Eris Lifesciences Ltd YoY Sales Growth of 6.91% and YoY Profit Growth of 31.23%.
What is the institutional holding pattern in ERIS?
ERIS has FII holding of 7.21% and DII holding of 19.36%. Significant institutional holding often suggests professional confidence in the Eris Lifesciences Ltd stock.